2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Review scientific discoveries and information presented by Dana-Farber physician-scientists at the 2026 ASCO Annual Meeting in Chicago, IL, May 29 - June 2, 2026.
ASCO26: David Reardon, MD, Glioblastoma Vaccine
Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders.
Medical Oncology
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
Medical Oncology
ASCO26: Julia Rotow, MD, Silevertinib in Lung Cancer
Dana-Farber Cancer Institute's Dr. Julia Rotow reported on a study looking at silevertinib, with data showing it may offer a new first-line option for hard-to-treat EGFR non-small cell lung cancer variants, with encouraging brain activity ...
Medical Oncology
ASCO26: Atish Choudhury, MD, PhD, A-DREAM/Alliance A032101
A-DREAM/Alliance A032101 study presented by Dana-Farber Cancer Institute's Dr. Atish Choudhury shows 41% of favorable responders to testosterone suppression plus androgen receptor pathway inhibitor remaining treatment-free with testosterone ...
Medical Oncology
ASCO26: Michael Hassett, MD, MPH, eSyM
Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements ...
Medical Oncology
ASCO26: Sara Tolaney, MD, MPH, ASCENT-04
Dana-Farber Cancer Institute's Dr. Sara Tolaney presented a subgroup analysis of the ASCENT-04 study based on biomarkers. Across all subgroups, patients who received sacituzumab govitecan plus pembro as first-line therapy had longer progression-free ...
Medical Oncology
ASCO26: Jennifer Ligibel, MD, BWEL
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients ...
Medical Oncology
ASCO26: Alicia Morgans, MD, MPH, ARACOG
Dr. Alicia Morgans of Dana-Farber Cancer Institute reported at #ASCO26 that ARACOG found darolutamide was associated with less decline in cognitive testing than enzalutamide, which may help guide treatment choice.
Medical Oncology
ASCO26: Toni Choueiri, MD, KEYNOTE-654
Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ...
Medical Oncology
2026 ASCO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates.
Medical Oncology
Medical Oncology
2026 ASCO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates
Medical Oncology
Medical Oncology
2026 ASCO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates
Medical Oncology
Medical Oncology
News Releases
- Dana-Farber Researchers to Present Two Plenary Studies and Additional Late-Breaking Cancer Research at 2026 ASCO
- RAS(ON) Inhibitor Doubles Median Overall Survival in Results of Phase 3 Trial for Patients with Metastatic Pancreatic Cancer
- Perioperative Apalutamide in High-Risk Localized or Locally Advanced Prostate Cancer Reduces Risk of Metastasis and Death
Resources
- Dana-Farber Oral Presentations at the 2026 ASCO Annual Meeting
- Dana-Farber Poster Discussions at the 2026 ASCO Annual Meeting
Awards & Honors
- Dana-Farber Giants in Cancer Care Award Recipients
- Head & Neck Cancer: Robert Haddad, MD
- Myeloma: Irene Ghobrial, MD
Follow us on social media
- X (formerly Twitter)
- @DanaFarber Cancer Institute - Information on our expert cancer care and advanced research
- @DanaFarberNews - Your source for Dana-Farber news
- @DFBC_PedCare - Dana-Farber/Boston Children's Cancer and Blood Disorders Center
- Bluesky